In 2022, Elizabeth Homans earned $1.86M in total compensation at Lyell Immunopharma, Inc., including $600.00K salary and $360.00K bonus. Led Lyell Immunopharma, Inc. as CEO for 1 years.
Compensation History
Annual executive compensation data for Elizabeth Homans, including salary, bonuses, and stock awards.
Year
2022
Total Compensation
$1.86M
Salary
$600.00K
Bonus
$360.00K
Other
$900.00K
Salary
$600.00KBoard Justification
The compensation philosophy is designed to attract and retain talented individuals who possess the skills necessary to manage and grow the business, facilitate the achievement of strategic goals, and create long-term value for stockholders.
Bonus
$360.00KBoard Justification
In connection with her termination of employment, Ms. Homans was paid $360,000, equal to 100% of her target bonus amount for 2022, as part of her severance benefits.
Other Compensation
$900.00KBoard Justification
In addition to her salary and bonus, Ms. Homans received a cash payment of $900,000, which constitutes the equivalent of 18 months of her annual base salary in effect as of the date of her termination of employment.
Restricted Stock
Board Justification
No stock was reported as vested in 2022 for Elizabeth Homans.
Performance Metrics
The performance metrics for determining the compensation included corporate goals related to advancing therapies and managing financial resources.
Elizabeth Homans
Ex-CEO of Lyell Immunopharma, Inc.
Education
MBA from Harvard Business School
Field of Expertise
Business & Management
Sector of Economy
Healthcare
Born
January 1, 1978 - 47 years ago
CEO of Lyell Immunopharma, Inc. for
1 year 2 months (Sep 2021 - Dec 2022)
Previous Experience
Former Chief Operating Officer at Lyell Immunopharma, Inc.
Other Lyell Immunopharma, Inc. CEOs
Holdings
Track Elizabeth Homans's stock holdings and portfolio value over time.
Insider Trading
Elizabeth Homans's recent stock transactions, purchases, and sales filed with the SEC.
No insider trades found for this CEO.
Rivals
Compare Elizabeth Homans with competitor CEOs and industry peers.